DRRX - デュレクト （DURECT Corporation） デュレクトDRRXのチャート
DRRXの企業情報
| symbol | DRRx |
|---|---|
| 会社名 | Durect Corp （デュレクト） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 ダレクト(Durect Corporation)は研究と開発に従事するバイオ医薬企業である。同社の候補製品は代謝/脂質障害向けの経口薬DUR-928、急性臓器傷害の注射可能薬DUR-928を含む。同社の他の製品候補はPOSIMIR（ブピバカインの制御放出注入）、REMOXY（経口制御放出オキシコドン）、ORADUR-ADHD、ELADUR（経口制御放出オキシコドン）、Relday（リスペリドン）、ORADURベースのオピオイド（ヒドロモルホン）、SABREベースの眼科薬を含む。同社のALZET製品ラインはマウス、ラットおよび他の実験動物の研究に使用される小型の移植可能な浸透圧ポンプと付属品を提供する。同社は製薬と医療機器クライアントの製品原材料に応用する標準およびカスタム生分解性ポリマーと賦形剤の生産と販売を行う。 デュレクトは米国の医薬品会社。慢性痛、術後疼痛、統合失調症、躁うつ症、注意欠陥多動性障害の治療薬に焦点を置く。「レモキシ―（経口オキシコドン）」、「ポジデュア(ブピバカイン注射剤)」、「エラデュア(経皮吸収ブピバカイン)」、リスペリドン系抗精神病薬、「オラデュア」の治験を行う。 DURECT is a biopharmaceutical company committed to transforming the treatment of acute organ injury and chronic liver diseases by advancing novel and potentially lifesaving therapies based on its endogenous epigenetic regulator program. DUR-928, the company's lead drug candidate is in clinical development for the potential treatment of alcohol-associated hepatitis (AH) for which FDA has granted a Fast Track Designation, COVID-19 patients with acute liver or kidney injury, and non-alcoholic steatohepatitis (NASH). DURECT's proprietary drug delivery technologies are designed to enable new indications and enhanced attributes for small-molecule and biologic drugs. One late-stage product candidate in this category is POSIMIR® (bupivacaine sustained-release solution), an investigational locally-acting, non-opioid analgesic intended to provide up to three days of continuous pain relief after surgery. |
| 本社所在地 | 10260 Bubb Road Cupertino CA 95014 USA |
| 代表者氏名 | Felix D Theeuwes フェリックス・テューウィーズ |
| 代表者役職名 | Chairman Chief Scientific Officer |
| 電話番号 | +1 408-777-1417 |
| 設立年月日 | 35827 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2000年 |
| 従業員数 | － |
| url | www.durect.com |
| nasdaq_url | https://www.nasdaq.com/symbol/drrx |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） 0.69000 |
| 終値（lastsale） | 1.07 |
| 時価総額（marketcap） | 173341767.64 |
| 時価総額 | 時価総額（百万ドル） 168.48170 |
| 売上高 | 売上高（百万ドル） 47.18500 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 145.94370 |
| 当期純利益 | 当期純利益（百万ドル） -0.96200 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 DURECT Corporation revenues decreased 22% to $6.9M. Net loss decreased 15% to $15.3M. Revenues reflect Product Revenues net decrease of 28% to $5.2M. Lower net loss reflects Other Research and development decrease of 22% to $12.4M (expense) Selling and general decrease of 13% to $5.4M (expense) Interest and other income increase from $75K to $398K (income). |
DRRXのテクニカル分析
DRRXのニュース
Durect Q4 2022 Earnings Preview 2023/03/06 22:35:20 Seeking Alpha
Durect (DRRX) is scheduled to announce Q4 earnings results on Tuesday, March 7th, after market close.The consensus EPS Estimate is -$0.55 (-1733.3% Y/Y) and the consensus Revenue…
Durect''s Earnings Outlook 2023/03/06 17:02:05 Benzinga
Durect (NASDAQ: DRRX ) is set to give its latest quarterly earnings report on Tuesday, 2023-03-07. Here''s what investors need to know before the announcement. Analysts estimate that Durect will report an earnings per share (EPS) of $-0.55. Durect bulls will hope to hear the company announce they''ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next … Full story available on Benzinga.com
DURECT Corporation to Announce Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 7 2023/02/28 23:07:00 PR Newswire
CUPERTINO, Calif., Feb. 28, 2023 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it will report its fourth quarter and full year 2022 financial results and host a conference call after the market close on Tuesday, March 7, 2023. Tuesday, March 7 @ 4:30pm Eastern…
7 Stocks Under $10 to Buy in February 2023/02/17 11:30:21 InvestorPlace
As an investor, you can get some amazing deals in the stock market. You can even fund some great stocks under $10 to buy if you know where to look. What’s the attraction to buying a stock under $10? Well, not everyone likes to spend $100 or more on a large-cap stock that carries a big price tag. Buying a stock under $10 means that for that same $100 you can pick up 10 shares instead of just one. Generally, stocks under $10 to buy are more likely to be growth stocks with longer runways to provide investors with some great returns. If you need help identifying stocks under $10 to buy, then I’ve got you covered. My Portfolio Grader tool evaluates and ranks stocks on an A through F scale based on a variety of metrics including earnings, recent performance, analyst sentiment and momentum. If you’re looking for stocks under $10 to buy, you can do a lot worse than these highly-rated picks. BBAI BigBear.ai $4.05 APPH AppHarvest $0.95 DRRX Durect 5.18 AUVI Applied UV $1.13 ARDX Ardelyx $3.04 LIZI Lizhi $1.01 RIG Transocean $7.57 BigBear.ai (BBAI) Source: whiteMocca / Shutterstock BigBear.ai (NASDAQ: BBAI ) may have an unusual name, but it’s one of the hottest stocks on Wall Street and one of the best stocks under $10 to buy.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday 2023/02/06 12:37:23 InvestorPlace
Source: ventdusud / Shutterstock.com We’re starting off the week with an overview of the biggest pre-market stock movers for Monday! Moving stocks this morning are funding updates, earnings, and stock offerings. Let’s get into that news below! Pre-Market Stock Movers: 10 Top Gainers Secoo Holding (NASDAQ: SECO ) stock is rocketing more than 77% alongside heavy pre-market trading. Jiuzi Holdings (NASDAQ: JZXN ) shares are soaring over 45% as it also sees strong early morning trading on Monday. Kalera PLC (NASDAQ: KAL ) stock is surging more than 42%, which builds on Friday’s gains. Faraday Future (NASDAQ: FFIE ) shares are climbing over 34% after obtaining funding for electric vehicle (EV) production. Elys Game Technology (NASDAQ: ELYS ) stock is gaining more than 28% following an update on debentures and warrants . Catalent (NYSE: CTLT ) shares are increasing over 28% on reports Danaher (NYSE: DHR ) may want to acquire the company . T Stamp (NASDAQ: IDAI ) stock is heading more than 28% higher this morning.
Durect Corp PT Raised to $35 at H.C. Wainwright 2022/12/06 11:50:04 Investing.com
https://www.investing.com/news/pro/durect-corp-pt-raised-to-35-at-hc-wainwright-432SI-2958185
Should You Expect A Quick Recovery From DURECT Corporation (NASDAQ: DRRX) After -172.5% Decline From High? 2022/12/03 17:00:00 Marketing Sentinel
DURECT Corporation (NASDAQ:DRRX)’s traded shares stood at 0.32 million during the last session, with the company’s beta value hitting 1.23. At the close of trading, the stock’s price was $0.40, to imply a decrease of -2.61% or -$0.01 in intraday trading. The DRRX share’s 52-week high remains $1.09, putting it -172.5% down since that peak … Should You Expect A Quick Recovery From DURECT Corporation (NASDAQ: DRRX) After -172.5% Decline From High? Read More »
DURECT Announces 1-for-10 Reverse Stock Split 2022/11/28 23:46:00 Benzinga
CUPERTINO, Calif. , Nov. 28, 2022 /PRNewswire/ -- DURECT Corporation (NASDAQ: DRRX ), a biopharmaceutical company focused on developing epigenetic regulator programs for the treatment of acute organ injury and chronic liver diseases, announced that DURECT''s board of directors today determined that the Company will effect a reverse stock split at a ratio of 1-for-10 as of 5:01 p.m. Eastern Time on December 5, 2022 . Beginning with the opening of trading on December 6, 2022 , the Company''s common stock will trade on a split-adjusted basis. At a Special Meeting of Stockholders held on November 22, 2022 , DURECT stockholders voted to approve a proposal authorizing the board of directors of the Company to amend the Company''s certificate of incorporation to effect a reverse stock split of DURECT''s outstanding common shares at an exchange ratio of not less than 1-for-10 and not greater than 1-for-20, and a reduction in the number of authorized shares of common stock from 600,000,000 to 150,000,000 shares.
DURECT Corporation (DRRX) Q3 2022 Earnings Call Transcript 2022/11/03 00:32:03 Seeking Alpha
DURECT Corporation (NASDAQ:NASDAQ:DRRX) Q3 2022 Earnings Conference Call November 02, 2022, 04:30 PM ET Company Participants Tim Papp - Chief Financial Officer Jim Brown - Chief Executive…
Durect GAAP EPS of -$0.01 in-line, revenue of $11.98M misses by $1.01M (NASDAQ:DRRX) 2022/11/02 20:18:40 Seeking Alpha
Durect press release (DRRX): Q3 GAAP EPS of -$0.01 in-line.Revenue of $11.98M (vs
DURECT Co. (NASDAQ:DRRX) Shares Purchased by Charles Schwab Investment Management Inc. 2021/11/30 10:56:41 Dakota Financial News
Charles Schwab Investment Management Inc. increased its stake in shares of DURECT Co. (NASDAQ:DRRX) by 4.8% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 573,991 shares of the specialty pharmaceutical companys stock after purchasing an additional 26,288 shares during the period. Charles []
DURECT Co. (NASDAQ:DRRX) Stock Position Trimmed by California State Teachers Retirement System 2021/11/30 10:14:44 Dakota Financial News
California State Teachers Retirement System cut its position in DURECT Co. (NASDAQ:DRRX) by 7.1% during the 2nd quarter, HoldingsChannel reports. The firm owned 312,482 shares of the specialty pharmaceutical companys stock after selling 23,890 shares during the quarter. California State Teachers Retirement Systems holdings in DURECT were worth $509,000 as of its most recent filing []
Nuveen Asset Management LLC Sells 64,997 Shares of DURECT Co. (NASDAQ:DRRX) 2021/11/26 09:54:41 Transcript Daily
Nuveen Asset Management LLC cut its stake in shares of DURECT Co. (NASDAQ:DRRX) by 6.5% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 932,510 shares of the specialty pharmaceutical companys stock after selling 64,997 shares during the quarter. Nuveen Asset Management LLC []
DURECT Co. (NASDAQ:DRRX) Shares Sold by MetLife Investment Management LLC 2021/11/24 10:34:41 Dakota Financial News
MetLife Investment Management LLC decreased its position in shares of DURECT Co. (NASDAQ:DRRX) by 74.0% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 24,530 shares of the specialty pharmaceutical companys stock after selling 69,869 shares during the period. MetLife Investment Management []
Data-Based Insights About DURECT Corporation (DRRX) 2021/11/19 15:00:00 Stocks Register
DURECT Corporation (NASDAQ:DRRX) price on Thursday, November 18, rose 1.80% above its previous days close as an upside momentum from buyers pushed the stocks value to $1.13. A look at the stocks price movement, the close in the last trading session was $1.11, moving within a range at $1.10 and $1.19. The beta value (5-Year Data-Based Insights About DURECT Corporation (DRRX) Read More »